Proinflammatory signals and the loss of lymphatic vessel hyaluronan receptor-1 (LYVE-1) in the early pathogenesis of laminin alpha2-deficient skeletal muscle

Journal of Histochemistry and Cytochemistry

Volumn 59, Issue 2, 2011, Pages 167-179

  Wardrop, Katherine E ^a   Dominov, Janice A ^a  

^a BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Congenital muscular dystrophy; Inflammation; Laminin alpha2; LYVE 1; Muscle; Tenascin c

Indexed keywords

BIOLOGICAL MARKER; CARDIOTOXIN; DYSTROPHIN; LAMININ ALPHA2; LYMPHATIC VESSEL HYALURONAN RECEPTOR 1; TENASCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GLYCOPROTEIN; INTERLEUKIN 1BETA; LAMININ; XLKD1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGENITAL MUSCULAR DYSTROPHY TYPE IA; CONTROLLED STUDY; ENDOMYSIUM; GENE EXPRESSION; LAMININ ALPHA2 DEFICIENT SKELETAL MUSCLE; MACROPHAGE; MOUSE; MUSCLE CELL; MUSCULAR DYSTROPHY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CYTOLOGY; DOWN REGULATION; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MUSCLE DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; SKELETAL MUSCLE; TIME;

ANIMALS; DOWN-REGULATION; GLYCOPROTEINS; INFLAMMATION; INTERLEUKIN-1BETA; LAMININ; MACROPHAGES; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; MUSCULAR DISEASES; SIGNAL TRANSDUCTION; TENASCIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953795991     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/jhc.2010.956672     Document Type: Article

References (53)

1. Arimoto J, Ikura Y, Suekane T, Nakagawa M, Kitabayashi C, Iwasa Y, Sugioka K, Naruko T, Arakawa T, Ueda M. 2010. Expression of LYVE-1 in sinusoidal endothelium is reduced in chronically inflamed human livers. J Gastroenterol. 45(3):317-325.
2. Bentzinger CF, Barzaghi P, Lin S, Ruegg MA. 2005. Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha2-deficient mice. FASEB J. 19:934-942.
3. Bushby K, Lochmuller H, Lynn S, Straub V. 2009. Interventions for muscular dystrophy: molecular medicines entering the clinic. Lancet. 374:1849-1856.
4. Chiquet M, Fambrough DM. 1984. Chick myotendinous antigen, I: a monoclonal antibody as a marker for tendon and muscle morphogenesis. J Cell Biol. 98:1926-1936.
5. Chiquet-Ehrismann R, Chiquet M. 2003. Tenascins: regulation and putative functions during pathological stress. J Pathol. 200:488-499.
6. Connolly AM, Keeling RM, Streif EM, Pestronk A, Mehta S. 2002. Complement 3 deficiency and oral prednisolone improve strength and prolong survival of laminin alpha2-deficient mice. J Neuroimmunol. 127:80-87.
7. Cueni LN, Detmar M. 2008. The lymphatic system in health and disease. Lymphat Res Biol. 6:109-122.
8. Dominov JA, Kravetz AJ, Ardelt M, Kostek CA, Beermann ML, Miller JB. 2005. Muscle-specific BCL2 expression amelioratesmuscle disease in laminin {alpha}2-deficient, but not in dystrophin-deficient, mice. Hum Mol Genet. 14:1029-1040.
9. Durbeej M. 2010. Laminins. Cell Tissue Res. 339:259-268.
10. El-Karef A, Yoshida T, Gabazza EC, Nishioka T, Inada H, Sakakura T, Imanaka-Yoshida K. 2007. Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J Pathol. 211:86-94.
11. Erb M, Meinen S, Barzaghi P, Sumanovski LT, Courdier-Fruh I, Ruegg MA, Meier T. 2009. Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-alpha2 deficiency. J Pharmacol Exp Ther. 331:787-795.
12. Evans NP, Misyak SA, Robertson JL, Bassaganya-Riera J, Grange RW. 2009. Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy. Am J Phys Med Rehabil. 88:502-522.
13. Flister MJ, Wilber A, Hall KL, Iwata C, Miyazono K, Nisato RE, Pepper MS, Zawieja DC, Ran S. 2010. Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood. 115:418-429.
14. Gale NW, Prevo R, Espinosa J, Ferguson DJ, Dominguez MG, Yancopoulos GD, Thurston G, Jackson DG. 2007. Normallymphatic development and function in mice deficient for the lymphatic hyaluronan receptor LYVE-1. Mol Cell Biol. 27:595-604.
15. Gawlik KI, Mayer U, Blomberg K, Sonnenberg A, Ekblom P, Durbeej M. 2006. Laminin alpha1 chain mediated reduction of laminin alpha2 chain deficient muscular dystrophy involves integrin alpha7beta1 and dystroglycan. FEBS Lett. 580:1759-1765.
16. Girgenrath M, Beermann ML, Vishnudas VK, Homma S, Miller JB. 2009. Pathology is alleviated by doxycycline in a lamininalpha2-null model of congenital muscular dystrophy. Ann Neurol. 65:47-56.
17. Girgenrath M, Dominov JA, Kostek CA, Boone Miller J. 2004.Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy. J Clin Invest. 114:1635-1639.
18. Hayashi YK, Tezak Z, Momoi T, Nonaka I, Garcia CA, Hoffman EP, Arahata K. 2001. Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy.Neuromuscul Disord. 11:350-359.
19. Helbling-Leclerc A, Zhang X, Topaloglu H, Cruaud C, Tesson F, Weissenbach J, Tome FM, Schwartz K, Fardeau M, Tryggvason K, et al. 1995. Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet. 11:216-218.
20. Jackson DG. 2004. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS. 112:526-538.
21. Jackson DG. 2009. Immunological functions of hyaluronan and its receptors in the lymphatics. Immunol Rev. 230:216-231.
22. Jarvinen TA, Kannus P, Jarvinen TL, Jozsa L, Kalimo H, Jarvinen M. 2000. Tenascin-C in the pathobiology and healing process of musculoskeletal tissue injury. Scand J Med Sci Sports. 10:376-382.
23. Johnson LA, Prevo R, Clasper S, Jackson DG. 2007. Inflammationinduced uptake and degradation of the lymphatic endothelial hyaluronan receptor LYVE-1. J Biol Chem. 282:33671-33680.
24. Kivela R, Havas E, Vihko V. 2007. Localisation of lymphatic vessels and vascular endothelial growth factors-C and -D in human and mouse skeletal muscle with immunohistochemistry. Histochem Cell Biol. 127:31-40.
25. Kriehuber E, Breiteneder-Geleff S, Groeger M, Soleiman A, Schoppmann SF, Stingl G, Kerjaschki D, Maurer D. 2001. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J Exp Med. 194:797-808.
26. Kuang W, Xu H, Vachon PH, Liu L, Loechel F, Wewer UM, Engvall E. 1998. Merosin-deficient congenital muscular dystrophy: partial genetic correction in two mouse models. J Clin Invest. 102:844-852.
27. Kuang W, Xu H, Vilquin JT, Engvall E. 1999. Activation of the lama2 gene in muscle regeneration: abortive regeneration in laminin alpha2-deficiency. Lab Invest. 79:1601-1613.
28. Li ZF, Shelton GD, Engvall E. 2005. Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality. Am J Pathol. 166:491-497.
29. Lundberg I, Brengman JM, Engel AG. 1995. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol. 63:9-16.
30. Luong MX, Tam J, Lin Q, Hagendoorn J, Moore KJ, Padera TP, Seed B, Fukumura D, Kucherlapati R, Jain RK. 2009. Lack of lymphatic vessel phenotype in LYVE-1/CD44 double knockout mice. J Cell Physiol. 219:430-437.
31. Maby-El Hajjami H, Petrova TV. 2008. Developmental and pathological lymphangiogenesis: from models to human disease. Histochem Cell Biol. 130:1063-1078.
32. Meinen S, Barzaghi P, Lin S, Lochmuller H, Ruegg MA. 2007. Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages. J Cell Biol. 176:979-993.
33. Miyagoe Y, Hanaoka K, Nonaka I, Hayasaka M, Nabeshima Y, Arahata K, Takeda S. 1997. Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. FEBS Lett. 415:33-39.
34. Moll J, Barzaghi P, Lin S, Bezakova G, Lochmuller H, Engvall E, Muller U, Ruegg MA. 2001. An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature. 413:302-307.
35. Mouta Carreira C, Nasser SM, di Tomaso E, Padera TP, Boucher Y, Tomarev SI, Jain RK. 2001. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res. 61:8079-8084.
36. Mrak RE. 1998. The pathologic spectrum of merosin deficiency. J Child Neurol. 13:513-515.
37. Mukasa T, Momoi T, Momoi MY. 1999. Activation of caspase-3apoptotic pathways in skeletal muscle fibers in laminin alpha2-deficient mice. Biochem Biophys Res Commun. 260:139-142.
38. Muller-Felber W, Toepfer M, Muller T, Muller-Hocker J, Fischer P, Lochmuller H, Pongratz D. 1998. Tenascin is a usefulmarker in the diagnosis of inflammatory myopathies. Eur J Med Res. 3:281-287.
39. Nagaraju K, Rawat R, Veszelovszky E, Thapliyal R, Kesari A, parks S, Raben N, Plotz P, Hoffman EP. 2008. Dysferlin deficiency enhances monocyte phagocytosis: a model for theinflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol. 172:774-785.
40. Nightingale TD, Frayne ME, Clasper S, Banerji S, Jackson DG. 2009. A mechanism of sialylation functionally silences the hyaluronan receptor LYVE-1 in lymphatic endothelium. J Biol Chem. 284:3935-3945.
41. Overbergh L, Valckx D, Waer M, Mathieu C. 1999. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine. 11:305-312.
42. Pegoraro E, Mancias P, Swerdlow SH, Raikow RB, Garcia C, Marks H, Crawford T, Carver V, Di Cianno B, Hoffman EP. 1996. Congenital muscular dystrophy with primary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy. Ann Neurol. 40:782-791.
43. Qiao C, Li J, Zhu T, Draviam R, Watkins S, Ye X, Chen C, Li J, Xiao X. 2005. Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin. Proc Natl Acad Sci U S A. 102:11999-12004.
44. Reggiani C, Brocks L, Wirtz P, Loermans H, te Kronnie G. 1992. Myosin isoforms in hindlimb muscles of normal and dystrophic (ReJ129 dy/dy) mice. Muscle Nerve. 15:199-208.
45. Ringelmann B, Roder C, Hallmann R, Maley M, Davies M, Grounds M, Sorokin L. 1999. Expression of laminin alpha1, alpha2, alpha4, and alpha5 chains, fibronectin, and tenascin-C in skeletal muscle of dystrophic 129ReJ dy/dy mice. Exp Cell Res. 246:165-182.
46. Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K. 1998. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem. 273:8413-8418.
47. Sapadin AN, Fleischmajer R. 2006. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 54:258-265.
48. Tammela T, Alitalo K. 2010. Lymphangiogenesis: molecular mechanisms and future promise. Cell. 140:460-476
49. Tidball JG, Villalta SA. 2010. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol. 298:1173-1187.
50. Tucker RP, Chiquet-Ehrismann R. 2009. The regulation of tenascin expression by tissue microenvironments. Biochim Biophys Acta. 1793:888-892.
51. Vachon PH, Loechel F, Xu H, Wewer UM, Engvall E. 1996. Merosin and laminin in myogenesis; specific requirement for merosin in myotube stability and survival. J Cell Biol. 134:1483-1497.
52. van Lunteren E, Moyer M, Leahy P. 2006. Gene expression profiling of diaphragm muscle in alpha2-laminin (merosin)-deficient dy/dy dystrophic mice. Physiol Genomics. 25:85-95.
53. Xu H, Wu XR, Wewer UM, Engvall E. 1994. Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene. Nat Genet. 8:297-302.